Walvax Biotechnology Co., Ltd. (SHE:300142)
China · Delayed Price · Currency is CNY 12.52
+0.94 (8.12%)
Jul 24, 2025, 10:45 AM CST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2016 - 2018 |
Autonomous Vaccine | 4.08B | Log In | Log In | Log In | Log In | Upgrade |
Intermediate Products | 17.22M | Log In | Log In | Log In | Log In | Upgrade |
Intermediate Products Growth | -36.61% | Log In | Log In | Log In | Log In | Upgrade |
Technical Services | 11.02M | Log In | Log In | Log In | Log In | Upgrade |
Technical Services Growth | -33.40% | Log In | Log In | Log In | Log In | Upgrade |
Other Business | 7.92M | Log In | Log In | Log In | Log In | Upgrade |
Other Business Growth | 3.51% | Log In | Log In | Log In | Log In | Upgrade |
Non-immunization Program Vaccines | - | Log In | Log In | Log In | Log In | Upgrade |
Immunization Program Vaccines | - | Log In | Log In | Log In | Log In | Upgrade |
13-valent Pneumococcal Polysaccharide Conjugate Vaccine | - | Log In | Log In | Log In | Log In | Upgrade |
23-valent Pneumococcal Polysaccharide Vaccine | - | Log In | Log In | Log In | Log In | Upgrade |
Haemophilus Influenza Type B | - | Log In | Log In | Log In | Log In | Upgrade |
Freeze-dried AC Vaccine Group Meningococcal Polysaccharide Conjugate Vaccine | - | Log In | Log In | Log In | Log In | Upgrade |
Group A and C Meningococcal Polysaccharide Vaccine | - | Log In | Log In | Log In | Log In | Upgrade |
ACYW135 Meningococcal Polysaccharide Vaccine | - | Log In | Log In | Log In | Log In | Upgrade |
Absorbed Acellular Diphtheria Combined Vaccine | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Production | - | Log In | Log In | Log In | Log In | Upgrade |
Production Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Research and Development | - | Log In | Log In | Log In | Log In | Upgrade |
Research and Development Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Inter-segment Eliminations | - | Log In | Log In | Log In | Log In | Upgrade |
Inter-segment Eliminations Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Inter-segment Eliminations | - | Log In | Log In | Log In | Log In | Upgrade |
Inter-segment Eliminations Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2016 - 2018 |
Inter-segment Eliminations | - | Log In | Log In | Log In | Log In | Upgrade |
Inter-segment Eliminations Growth | - | Log In | Log In | Log In | Log In | Upgrade |
China | 3.83B | Log In | Log In | Log In | Log In | Upgrade |
China Growth | -20.34% | Log In | Log In | Log In | Log In | Upgrade |
Overseas | 287.54M | Log In | Log In | Log In | Log In | Upgrade |
Overseas Growth | 1.46% | Log In | Log In | Log In | Log In | Upgrade |
Inter-segment Eliminations | - | Log In | Log In | Log In | Log In | Upgrade |
Inter-segment Eliminations Growth | - | Log In | Log In | Log In | Log In | Upgrade |